Effect of Avatrombopag on platelets

Avatrombopagis a thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled for surgery and thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an inadequate response to prior therapy.

Avatrombopag (an oral thrombopoietin receptor agonist) versus placebo in a 6 month, multicenter, randomized, double-blind, parallel group3The median number of platelet reaction weeks( is 12±4 weeks and 0±0weeks) is better than placebo(N = 17); P < 0 0001). A higher platelet response rate was also observed in patients treated with avatrombopag compared with placebo on day 8 (65 63% vs. 0 The use of concomitant ITP medications was also reduced in Avatropopag patients ; Safety and Avatropopag The phase 2 studies were consistent; the most common adverse events were headache and contusion. Overall, avatrombopag was well tolerated and effective in treating chronic ITP.

Approximately one box of imitation version600 to 900 or so, a box of 28 capsules. If you want to get more high-quality information, you can contact Yaode, and Yaode will do its best to help you learn more about high-quality overseas drugs.

xa0

xa0